Cargando…

Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients

Using data from the real world to solve clinical questions that cannot be answered using data from clinical trials is attracting more attention. Clinical outcomes for patients with esophageal cancer in a real-world setting might be different from data in randomized controlled trials. This study aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Hye-Kyung, Tae, Chung Hyun, Lee, Hye-Ah, Lee, Hyuk, Don Choi, Kee, Park, Jun Chul, Kwon, Joong Goo, Choi, Yoon Jin, Hong, Su Jin, Sung, Jaekyu, Chung, Woo Chul, Kim, Ki Bae, Kim, Seung Young, Song, Kyung Ho, Park, Kyung Sik, Jeon, Seong Woo, Kim, Byung-Wook, Ryu, Han Seung, Lee, Ok-Jae, Baik, Gwang Ho, Kim, Yong Sung, Jung, Hwoon-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147737/
https://www.ncbi.nlm.nih.gov/pubmed/32275699
http://dx.doi.org/10.1371/journal.pone.0231456
_version_ 1783520471825776640
author Jung, Hye-Kyung
Tae, Chung Hyun
Lee, Hye-Ah
Lee, Hyuk
Don Choi, Kee
Park, Jun Chul
Kwon, Joong Goo
Choi, Yoon Jin
Hong, Su Jin
Sung, Jaekyu
Chung, Woo Chul
Kim, Ki Bae
Kim, Seung Young
Song, Kyung Ho
Park, Kyung Sik
Jeon, Seong Woo
Kim, Byung-Wook
Ryu, Han Seung
Lee, Ok-Jae
Baik, Gwang Ho
Kim, Yong Sung
Jung, Hwoon-Yong
author_facet Jung, Hye-Kyung
Tae, Chung Hyun
Lee, Hye-Ah
Lee, Hyuk
Don Choi, Kee
Park, Jun Chul
Kwon, Joong Goo
Choi, Yoon Jin
Hong, Su Jin
Sung, Jaekyu
Chung, Woo Chul
Kim, Ki Bae
Kim, Seung Young
Song, Kyung Ho
Park, Kyung Sik
Jeon, Seong Woo
Kim, Byung-Wook
Ryu, Han Seung
Lee, Ok-Jae
Baik, Gwang Ho
Kim, Yong Sung
Jung, Hwoon-Yong
author_sort Jung, Hye-Kyung
collection PubMed
description Using data from the real world to solve clinical questions that cannot be answered using data from clinical trials is attracting more attention. Clinical outcomes for patients with esophageal cancer in a real-world setting might be different from data in randomized controlled trials. This study aimed to provide real world data on treatment and prognosis in Korean patients with esophageal cancer. This retrospective cancer cohort included newly diagnosed cases of esophageal cancer at 19 tertiary hospitals between January 1, 2005 and December 31, 2017. Cancer staging was defined according to the 7th edition of the American Joint Committee on Cancer criteria. We identified 6,354 patients with newly diagnosed esophageal cancer (mean age: 64.9 ± 9.0 years, 96.9% squamous cell carcinoma). The proportion of early esophageal cancer increased from 24.7% in 2005 to 37.2% in 2015 (p<0.001). Among all cases, surgery alone was 31.3%, followed by definitive concurrent chemoradiotherapy (CCRT) (27.0%), neoadjuvant therapy (12.4%), adjuvant therapy (11.1%), and endoscopic resection (5.8%). The 5-year overall survival rate was 45.7 ± 0.7%. Endoscopic resection provided similar median survival relative to surgery for stage Ia cases. Among stage II–III cases, definitive CCRT was associated with poorer survival than neoadjuvant or adjuvant therapy, although there was no survival difference between neo-adjuvant and adjuvant therapy. Early esophageal cancer is gradually becoming more common and endoscopic resection provided similar long-term survival relative to surgery. Surgery with combined therapy provided better survival in locally advanced esophageal cancer, relative to definitive CCRT.
format Online
Article
Text
id pubmed-7147737
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-71477372020-04-14 Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients Jung, Hye-Kyung Tae, Chung Hyun Lee, Hye-Ah Lee, Hyuk Don Choi, Kee Park, Jun Chul Kwon, Joong Goo Choi, Yoon Jin Hong, Su Jin Sung, Jaekyu Chung, Woo Chul Kim, Ki Bae Kim, Seung Young Song, Kyung Ho Park, Kyung Sik Jeon, Seong Woo Kim, Byung-Wook Ryu, Han Seung Lee, Ok-Jae Baik, Gwang Ho Kim, Yong Sung Jung, Hwoon-Yong PLoS One Research Article Using data from the real world to solve clinical questions that cannot be answered using data from clinical trials is attracting more attention. Clinical outcomes for patients with esophageal cancer in a real-world setting might be different from data in randomized controlled trials. This study aimed to provide real world data on treatment and prognosis in Korean patients with esophageal cancer. This retrospective cancer cohort included newly diagnosed cases of esophageal cancer at 19 tertiary hospitals between January 1, 2005 and December 31, 2017. Cancer staging was defined according to the 7th edition of the American Joint Committee on Cancer criteria. We identified 6,354 patients with newly diagnosed esophageal cancer (mean age: 64.9 ± 9.0 years, 96.9% squamous cell carcinoma). The proportion of early esophageal cancer increased from 24.7% in 2005 to 37.2% in 2015 (p<0.001). Among all cases, surgery alone was 31.3%, followed by definitive concurrent chemoradiotherapy (CCRT) (27.0%), neoadjuvant therapy (12.4%), adjuvant therapy (11.1%), and endoscopic resection (5.8%). The 5-year overall survival rate was 45.7 ± 0.7%. Endoscopic resection provided similar median survival relative to surgery for stage Ia cases. Among stage II–III cases, definitive CCRT was associated with poorer survival than neoadjuvant or adjuvant therapy, although there was no survival difference between neo-adjuvant and adjuvant therapy. Early esophageal cancer is gradually becoming more common and endoscopic resection provided similar long-term survival relative to surgery. Surgery with combined therapy provided better survival in locally advanced esophageal cancer, relative to definitive CCRT. Public Library of Science 2020-04-10 /pmc/articles/PMC7147737/ /pubmed/32275699 http://dx.doi.org/10.1371/journal.pone.0231456 Text en © 2020 Jung et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Jung, Hye-Kyung
Tae, Chung Hyun
Lee, Hye-Ah
Lee, Hyuk
Don Choi, Kee
Park, Jun Chul
Kwon, Joong Goo
Choi, Yoon Jin
Hong, Su Jin
Sung, Jaekyu
Chung, Woo Chul
Kim, Ki Bae
Kim, Seung Young
Song, Kyung Ho
Park, Kyung Sik
Jeon, Seong Woo
Kim, Byung-Wook
Ryu, Han Seung
Lee, Ok-Jae
Baik, Gwang Ho
Kim, Yong Sung
Jung, Hwoon-Yong
Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients
title Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients
title_full Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients
title_fullStr Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients
title_full_unstemmed Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients
title_short Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients
title_sort treatment pattern and overall survival in esophageal cancer during a 13-year period: a nationwide cohort study of 6,354 korean patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147737/
https://www.ncbi.nlm.nih.gov/pubmed/32275699
http://dx.doi.org/10.1371/journal.pone.0231456
work_keys_str_mv AT junghyekyung treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT taechunghyun treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT leehyeah treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT leehyuk treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT donchoikee treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT parkjunchul treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT kwonjoonggoo treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT choiyoonjin treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT hongsujin treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT sungjaekyu treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT chungwoochul treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT kimkibae treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT kimseungyoung treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT songkyungho treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT parkkyungsik treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT jeonseongwoo treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT kimbyungwook treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT ryuhanseung treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT leeokjae treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT baikgwangho treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT kimyongsung treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT junghwoonyong treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients
AT treatmentpatternandoverallsurvivalinesophagealcancerduringa13yearperiodanationwidecohortstudyof6354koreanpatients